Climb Bio (CLYM) News Today $1.31 +0.04 (+3.15%) As of 01:08 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Climb Bio (NASDAQ:CLYM) Trading Down 2.4% - Should You Sell?Climb Bio (NASDAQ:CLYM) Stock Price Down 2.4% - What's Next?April 24, 2025 | marketbeat.comExec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REXApril 10, 2025 | finance.yahoo.comClimb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to boardApril 2, 2025 | markets.businessinsider.comQ2 Earnings Estimate for Climb Bio Issued By Leerink PartnrsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Investment analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for Climb Bio in a research report issued on Tuesday, March 25th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($0.15) per sMarch 29, 2025 | marketbeat.comClimb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update ReportMarch 27, 2025 | finance.yahoo.comClimb Bio to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 27, 2025 | globenewswire.comClimb Bio Advances Clinical Trials and Expands PipelineMarch 27, 2025 | tipranks.comClimb Bio (NASDAQ:CLYM) Releases Earnings Results, Beats Estimates By $0.02 EPSClimb Bio (NASDAQ:CLYM - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02.March 26, 2025 | marketbeat.comClimb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 26, 2025 | finanznachrichten.deClimb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 25, 2025 | globenewswire.comClimb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation ReportMarch 20, 2025 | finance.yahoo.comClimb Bio (CLYM) Expected to Announce Earnings on ThursdayClimb Bio (NASDAQ:CLYM) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Shares Down 6.9% - Should You Sell?Climb Bio (NASDAQ:CLYM) Trading Down 6.9% - What's Next?March 4, 2025 | marketbeat.comClimb Bio to Present at Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comClimb Bio appoints Perrin Wilson as CBOFebruary 24, 2025 | markets.businessinsider.comClimb Bio Appoints Perrin Wilson, Ph.D., as Chief Business OfficerFebruary 24, 2025 | globenewswire.comCLYM Stock Touches 52-Week Low at $1.5 Amid Market ChallengesFebruary 12, 2025 | msn.comClimb Bio FY2025 EPS Forecast Decreased by Leerink PartnrsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Climb Bio in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($0.66) per share for theFebruary 10, 2025 | marketbeat.comLeerink Partnrs Comments on Climb Bio FY2029 EarningsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings estimates for Climb Bio in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($2.73) per share for the yeFebruary 7, 2025 | marketbeat.comClimb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comClimb Bio (NASDAQ:CLYM) Trading Down 0.5% - Should You Sell?Climb Bio (NASDAQ:CLYM) Trading Down 0.5% - Time to Sell?January 23, 2025 | marketbeat.comLeerink Partners Sticks to Its Buy Rating for Climb Bio (CLYM)January 13, 2025 | markets.businessinsider.comClimb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA NephropathyJanuary 9, 2025 | globenewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)January 2, 2025 | prnewswire.comClimb Bio Inc (CLYM)December 30, 2024 | investing.comClimb Bio to be added to Nasdaq Biotechnology IndexDecember 20, 2024 | markets.businessinsider.comClimb Bio to be Added to the Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comLeerink Partnrs Comments on Climb Bio FY2024 EarningsClimb Bio, Inc. (NASDAQ:CLYM - Free Report) - Equities researchers at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Climb Bio in a research report issued on Monday, December 2nd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per sharDecember 4, 2024 | marketbeat.com Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address CLYM Media Mentions By Week CLYM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLYM News Sentiment▼0.000.72▲Average Medical News Sentiment CLYM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLYM Articles This Week▼01▲CLYM Articles Average Week Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Benitec Biopharma News Today Entrada Therapeutics News Today MBX Biosciences News Today Monte Rosa Therapeutics News Today Cartesian Therapeutics News Today Atai Life Sciences News Today Atyr PHARMA News Today Compass Therapeutics News Today Cryoport News Today Astria Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLYM) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLYM Stock Free CLYM Stock Alerts